Combined Antiinflammatory and Angiostatic Therapy in Patients With Hormone-refractory Prostate Cancer

Exclusion Criteria

• •Change of hormone therapy within 6 weeks prior inclusion
• •Prior chemotherapy
• •Therapy with Imatinib, or therapy with other inhibitors of tyrosinkinase.
• •Second neoplasm diagnosed within 5 years before study start.
• •Patients who require therapy with warfarin
• •Known diagnosis of HIV, hepatitis B, or hepatitis C infection.
• •Severe, unstable, or uncontrolled medical disease which would confound diagnoses or evaluations required by the protocol, including severe cardiac insufficiency
• •Surgical therapy within 4 weeks before inclusion.
• •Prior therapy with isotopes strontium or rhenium.
• •Radiation therapy to \> 25% of bone marrow within 4 weeks before inclusion.
• •Treatment with other experimental substances within 30 days before study start.